RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis ...Middle East

With this approval, RINVOQ® (upadacitinib 15 mg, once daily) is the first and only Janus Kinase (JAK) inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the European Union (EU)1 Approval is supported by data from...

Read More Details
Finally We wish PressBee provided you with enough information of ( RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis )

Also on site :

• Which Stevie Nicks Song Matches You, Based on Zodiac Sign
• At least 35 killed in new Israeli attack on Gaza aid seekers
• Aldi Shoppers Say New Freezer Find 'Doesn't Disappoint'